Skip to main content

Table 3 All Enterobacterales isolates: adjusted estimates for resistance over time and by geographic region

From: A multicenter analysis of trends in resistance in urinary Enterobacterales isolates from ambulatory patients in the United States: 2011–2020

Characteristics

ESBL

Beta-lactam

Trimethoprim/sulfamethoxazole

Fluoroquinolone

Nitrofurantoin

Est (95% CI)

P

Est (95% CI)

P

Est (95% CI)

P

Est (95% CI)

P

Est (95% CI)

P

Year

 

< 0.001

 

< 0.001

 

< 0.001

 

< 0.001

 

< 0.001

 2011

6.5 (6.3–6.8)

 

60.5 (60.2–60.9)

 

25.7 (25.1–26.2)

 

25.6 (25.0–26.2)

 

21.6 (21.1–22.4)

 

 2012

6.8 (6.5–7.0)

 

59.9 (59.5–60.3)

 

26.5 (25.9–27.0)

 

25.0 (24.4–25.5)

 

23.1 (22.5–23.9)

 

 2013

6.9 (6.7–7.1)

 

59.0 (58.6–59.4)

 

26.2 (25.6–26.8)

 

24.2 (23.7–24.8)

 

22.4 (21.9–23.2)

 

 2014

7.3 (7.1–7.6)

 

58.4 (58.0–58.8)

 

25.7 (25.1–26.2)

 

23.8 (23.3–24.4)

 

22.5 (21.9–23.3)

 

 2015

7.5 (7.3–7.8)

 

57.7 (57.3–58.1)

 

25.6 (25.0–26.2)

 

23.2 (22.7–23.8)

 

20.9 (20.4–21.8)

 

 2016

7.8 (7.5–8.0)

 

57.2 (56.7–57.5)

 

24.8 (24.2–25.4)

 

22.7 (22.1–23.3)

 

18.9 (18.4–19.8)

 

 2017

8.2 (7.9–8.5)

 

56.9 (56.5–57.4)

 

24.6 (23.9–25.2)

 

22.3 (21.7–23.0)

 

19.0 (18.4–19.9)

 

 2018

8.6 (8.3–8.8)

 

56.6 (56.2–57.0)

 

24.5 (23.9–25.1)

 

22.1 (21.5–22.8)

 

20.2 (19.7–21.1)

 

 2019

8.9 (8.7–9.2)

 

56.3 (55.8–56.7)

 

24.6 (23.9–25.1)

 

22.2 (21.5–22.8)

 

21.9 (21.4–22.7)

 

 2020

9.4 (9.1–9.6)

 

56.1 (55.6–56.4)

 

23.9 (23.2–24.4)

 

21.9 (21.3–22.5)

 

22.3 (21.7–23.1)

 

Season (quarter)

 

0.015

 

0.009

 

< 0.001

 

< 0.0001

 

< 0.001

 1

8.2 (6.5–9.9)

 

57.8 (56.7–58.9)

 

25.4 (24.2–26.2)

 

23.5 (22.2–24.7)

 

20.8 (18.6–22.8)

 

 2

8.1 (6.3–9.9)

 

57.5 (56.3–58.5)

 

25.3 (24.1–26.2)

 

23.1 (21.8–24.3)

 

20.7 (18.4–22.7)

 

 3

7.9 (6.2–9.8)

 

56.9 (55.7–57.9)

 

24.3 (23.1–25.2)

 

22.3 (21.0–23.6)

 

20.9 (18.5–22.9)

 

 4

8.3 (6.6–10.0)

 

57.2 (56.1–58.2)

 

24.7 (23.5–25.6)

 

22.7 (21.5–23.9)

 

21.9 (19.7–23.9)

 

Census regiona

 

0.003

 

< 0.001

 

< 0.001

 

< 0.001

 

0.005

 East North Central

5.7 (3.7–7.6)

 

55.9 (54.4–57.3)

 

21.6 (19.8–22.9)

 

18.7 (16.9–20.5)

 

20.2 (17.6–23.0)

 

 East South Central

9.2 (7.2–11.1)

 

64.2 (62.6–65.7)

 

29.1 (27.3–30.4)

 

28.2 (26.3–30.0)

 

23.1 (20.4–25.7)

 

 Middle Atlantic

8.1 (6.2–10.1)

 

58.6 (57.2–60.1)

 

22.9 (21.1–24.1)

 

22.4 (20.6–24.2)

 

21.2 (18.6–24.1)

 

 Mountain

4.9 (3.0–6.9)

 

57.3 (55.9–58.8)

 

22.5 (20.6–23.7)

 

17.6 (15.8–19.4)

 

16.6 (14.0–19.2)

 

 New England

12.1 (10.9–13.3)

 

65.5 (64.5–66.5)

 

23.5 (21.9–24.7)

 

19.6 (18.4–20.9)

 

18.8 (16.6–21.4)

 

 Pacific

10.6 (8.6–12.5)

 

56.1 (54.6–57.6)

 

25.8 (24.0–27.1)

 

22.6 (20.8–24.4)

 

17.9 (15.2–20.5)

 

 South Atlantic

7.4 (5.4–9.3)

 

52.5 (51.0–54.0)

 

23.7 (21.9–25.0)

 

22.7 (20.9–24.5)

 

22.9 (20.3–25.6)

 

 West North Central

8.8 (7.6–10.0)

 

52.4 (51.4–53.3)

 

24.3 (22.8–25.5)

 

24.6 (23.4–25.8)

 

22.0 (19.9–24.6)

 

 West South Central

8.6 (6.6–10.5)

 

54.1 (52.7–55.6)

 

26.3 (24.4–27.7)

 

22.7 (20.9–24.5)

 

21.4 (18.7–24.1)

 
  1. CI confidence interval, ESBL extended-spectrum beta-lactamase-producing phenotype, Est estimated, NS not susceptible
  2. aStates included in the data sample by census regions were: East North Central: Illinois, Indiana, Michigan, Ohio, and Wisconsin; East South Central: Alabama, Kentucky, Mississippi, and Tennessee; Middle Atlantic: New Jersey, New York, and Pennsylvania; Mountain: Arizona, Idaho, Montana, and New Mexico; New England: Connecticut and New Hampshire; Pacific: California, Oregon, and Washington; South Atlantic: Delaware, Georgia, Florida, Maryland, North Carolina, South Carolina, Washington D.C., West Virginia, and Virginia; West North Central: Iowa and Missouri; West South Central: Louisiana, Oklahoma, Texas